Pancragen

Also known as: Pancreas Bioregulator, Pancreatic Peptide

A Khavinson bioregulator peptide for pancreatic function and glucose metabolism.

Overview

Pancragen is a synthetic tetrapeptide from the Khavinson bioregulator family designed to support pancreatic function. It may help normalize insulin production and glucose metabolism, particularly during aging or in metabolic disorders.

Mechanism of Action

Gene regulatory effects on pancreatic tissue. Proposed to normalize protein synthesis in beta cells and exocrine pancreas. May support insulin secretion and pancreatic enzyme production.

Pharmacokinetics

Small peptide allows oral/sublingual administration. Tissue-specific effects on pancreas.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Metabolic Support

Dose

10-20 mg

Frequency

1-2x daily

Duration

10-30 days

2-3 courses per year

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Glucose control

Synergy: Complementary metabolic support

Research Areas

DiabetesPancreatic FunctionGlucose MetabolismInsulin ProductionMetabolic AgingPrediabetes

Key Research Findings

  • 1Improved glucose tolerance in studies
  • 2Support for pancreatic beta cell function
  • 3Gene expression modulation in pancreatic tissue
  • 4Part of metabolic bioregulator protocols

Side Effects & Contraindications

Reported Side Effects

  • Generally well-tolerated
  • Monitor glucose levels

Contraindications

  • Acute pancreatitis

Safety Considerations

Generally well-tolerated. Monitor blood glucose. May complement but not replace diabetes medications.

Storage Requirements

Store at room temperature

Scientific References

Quick Reference

Sequence
Lys-Glu-Asp-Trp
Molecular Weight
~561 g/mol
Half-Life
Short
Bioavailability
Oral/sublingual
Research Stage
clinical phase 2
Administration
Oral or sublingual